- CDC’s advisory committee on vaccination practices voted Thursday to recommend boosters for certain at-risk groups
- ACIP was unable to recommend a third dose until the FDA approved emergency use authorization for a third dose on Wednesday
- The booster was recommended for use in people 65 years of age and older and those 18 to 64 years of age with underlying medical conditions
- Committee votes against recommending a third dose to people at high risk because of their jobs
- The recommendations only apply to people who have received two doses of the Pfizer-BioNTech vaccine.
The Centers for Disease Control and Prevention (CDC) advisory committee has officially recommended the use of booster doses for the Pfizer-BioNTech COVID-19 vaccine in specific groups.
Members of the Advisory Committee on Immunization Practices (ACIP) unanimously voted to give the shot to people 65 and older and long-term care facility residents and 13 to Americans aged 50 to 64 with underlying medical conditions. -2.
Boosters were also recommended for people aged 18 to 49 with pre-existing conditions, but passing the vote 9-6 was too close with the recommendation.
However, the committee voted against recommended use for people at risk due to ‘occupational or institutional settings’ including healthcare workers, grocery store workers, teachers and grocery store workers, as well as prisons or homeless shelters.
This comes less than 24 hours after the US Food and Drug Administration (FDA) authorized a third Pfizer dose for these groups.
Until the FDA announced its decision, ACIP was unable to recommend a third dose, a necessary step before pharmacists or physicians could immunize patients.
The CDC is not obligated to follow the advisory group’s recommendations, but the agency rarely goes against ACIP’s guidance.
CDC’s Advisory Committee on Immunization Practices voted Thursday to recommend boosters for certain at-risk groups Image: CDC Headquarters in Atlanta, Georgia
CDC’s advisory committee has voted to recommend the booster for use in people age 65 and older and those aged 50 to 64 with underlying medical conditions. Pictured: Nurse Kevin Grellman gives 80-year-old Jose Gomez, 80, a third booster dose of Pfizer’s vaccine after his wife. Armida Gomez, 81, welcomes her in August 2021 in Pasadena, California
Last month, boosters were approved for immunocompromised Americans who received the Pfizer or Moderna vaccine after data showed they were less likely to develop high antibody levels after two doses.
As of Friday, at least 2.3 million people in the US have received a booster dose, according to CDC data.
The White House also announced last month that booster shots will become available to all Americans starting September 20, as data suggests the effectiveness of the early shots has been downplayed.
At the time, Pfizer said its initial data showed that those who received a booster dose between six and 12 months after their last dose had a higher level of protection.
The company filed for emergency use authorization for the booster dose in late August and submitted the data to the FDA, which were made public last week.
NS documents suggest that protection from two doses of Pfizer vaccine decreases from 96.2 percent at seven days after dose 2 to 90.1 percent after two months to 83.7 percent after six months.
Pfizer said the data suggested a reduction in the efficacy of the two doses from 96.2% to 83.7% after six months, but the third dose increased antibody levels (above)
What’s more, he cited data from Israel showing people who were fully vaccinated in January 2021 had a 2.26-fold increased risk for breakthrough infection compared to those who were fully vaccinated in April 2021.
Another Israeli study discussed in the documents showed that the effectiveness against infection was 39 percent and against symptomatic disease was 40 percent from June 20, 2021 to July 17, 2021, when the delta variant was the dominant strain.
In comparison, between January and April, these rates were 95 per cent or more.
The team also released data from a clinical trial involving 23 Participants who took part in Pfizer’s early-stage trials last year.
Each had received two doses of the vaccine and was given a booster dose at least six months later.
11 of the participants were in Young adult groups aged 18 to 55 and 12 were aged 65 to 85.
After the third dose, neutralizing antibodies against the original strain of the virus increased five-fold in the 18 to 55 age group and seven-fold in the 65 to 85 age group.
Against the delta variant, antibody levels after the booster shot increased five-fold in the younger adult group and 12-fold in the older adult group.
But many scientists, including senior FDA officials, disagree and argue that vaccines are still highly effective in preventing serious illness and death.
FDA officials also expressed concern over the lack of data on the potential side effects of the third dose, especially for young adults who may be at risk of heart disease.
a different briefing document Also published last week, FDA scientists wrote in a skeptical tone about the need for booster shots.
Overall, the data indicate that currently US-licensed or authorized COVID-19 vaccines still provide protection against serious COVID-19 illness and death in the United States, the scientists wrote.
He added that studies on booster doses have presented conflicting findings and that there are ‘known and unknown biases that may affect their reliability’.